The rise of multidrug resistant tuberculosis (MDR-TB) is a growing global concern, driven by factors like the efflux pump Rv1258c, which contributes to antibiotic resistance and poor treatment outcomes.
In our research, we employed rational drug design and in silico techniques to identify potential efflux pump inhibitors (EPIs) aimed at Rv1258c, utilizing 210 phytocompounds for docking studies.
Our findings highlighted two promising compounds, ellagic acid and baicalein, which not only showed excellent docking scores but also demonstrated better drug-like properties compared to traditional EPIs, suggesting their potential for further development in combatting MDR-TB.